Aug 21, 2024 / 07:45AM GMT
Martin Olin - Bergenbio ASA - Chief Executive Officer
(spoken in foreign language)
So I'll do this in English. I'm Martin Olin, the CEO of BerGenBio. Welcome to the second quarter 2024 presentation. For those who have not heard about BerGenBio before, we all about excellent inhibition and why we're doing that, we're doing that because it's known that [Axel], which is a cell surface receptor, a protein, is involved and critical in a number of serious diseases.
I'm happy to report that on our very focused strategy, we progressed very well in the second quarter, particularly on the clinical and the financial aspects in the our main study, which is called BTBC 16, which is the study in frontline therapy in non-small cell lung cancer patients who have a mutation and gene called STK11, a significant unmet medical need.
I'm happy to report that we have completed all the three cohorts in the Phase Ib. So the Ib is a safety study, which tested three doses, 75, 100 milligram to 150 milligram, and we received a positive recommendation for the Data Safety Monitoring Board, allowing us to
Q2 2024 Bergenbio ASA Earnings Call Transcript
Aug 21, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers